Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Roflumilast Cream in Facial Papulopustular Rosacea
NCT05278624Phase 2Completed
- Sponsor
- Dermatology Consulting Services
- Start
- Apr 2022
- Primary completion
- Feb 2023
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of roflumilast vehicle cream in papulopustular rosacea (2 arms), sponsored by Dermatology Consulting Services. Primary endpoint: Reduction in rosacea facial inflammatory lesion count at 12 weeks. Started Apr 2022; status: completed.
02
Drugs
roflumilast vehicle cream
03
Conditions
papulopustular rosacea
Beyond the preview
Go deeper on NCT05278624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05278624.